| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701428 | Journal of Thoracic Oncology | 2017 | 20 Pages |
Abstract
PD-L1 expression in TMAs correlates moderately well with that in the corresponding surgical specimens, indicating that evaluating PD-L1 expression in diagnostic biopsy specimens could be misleading in defining sensitivity to pembrolizumab treatment yet may be reliable as a way to exclude patients with a PD-L1 TPS less than 50% from first-line pembrolizumab treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chao MD, PhD, Cheng MD, Tony S. MD, Wu MD, Haipeng MD, Qian MD, Xirong MD, Weifeng MD, Yunjian MD, Xiandong MD, PhD, Kan MD, Dan MD, PhD, Xiaohui MD, PhD, Peisha MD, Gen MD, PhD,